L Jost
Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
Köberle D, Thürlimann B, Pilop C, Crowe S, Öhlschlegel C, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller T, Swiss Group for Clinical Cancer Research (SAKK). Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03). Endocr Relat Cancer 2011; 18:257-64.
Mar 9, 2011Combination of trastuzumab and letrozole after resistance to sequential trastuzumab and aromatase inhibitor monotherapies in patients with estrogen receptor-positive, HER-2-positive advanced breast cancer: a proof-of-concept trial (SAKK 23/03)
Mar 9, 2011Endocr Relat Cancer 2011; 18:257-64
Köberle Dieter, Thürlimann Beat, Pilop C, Crowe S, Öhlschlegel Christian, von Moos R, Zaman K, Pagani O, Jost L, Ruhstaller Thomas, Swiss Group for Clinical Cancer Research (SAKK)
HIV-associated non-Hodgkin's lymphoma: highly active antiretroviral therapy improves remission rate of chemotherapy
Evison J, Jost J, Ledergerber B, Jost L, Strasser F, Weber R. HIV-associated non-Hodgkin's lymphoma: highly active antiretroviral therapy improves remission rate of chemotherapy. AIDS (London, England) 1999; 13:732-4.
Apr 16, 1999HIV-associated non-Hodgkin's lymphoma: highly active antiretroviral therapy improves remission rate of chemotherapy
Apr 16, 1999AIDS (London, England) 1999; 13:732-4
Evison J, Jost J, Ledergerber B, Jost L, Strasser Florian, Weber R